Small liver lesions in oncologic patients: characterization with CT, MRI and contrast-enhanced US by Morana G. et al.
Cancer Imaging (2008) 8, S132!S135
DOI: 10.1102/1470-7330.2008.9020
Small liver lesions in oncologic patients: characterization
with CT, MRI and contrast-enhanced US
Giovanni Morana, Christian Cugini and Raffaella Pozzi Mucelli
Radiological Department, General Hospital C !a Foncello, Piazza Ospedale 1, 31100 Treviso, Italy
Corresponding address: Dr Giovanni Morana, Radiological Department, General Hospital C !a Foncello,
Piazza Ospedale 1, 31100 Treviso, Italy.
Email: gmorana@ulss.tv.it
Abstract
Focal liver lesions (FLLs) are frequently discovered during ultrasound examinations either in healthy subjects without
a clinical history of cancer or during staging or follow-up procedures in oncologic patients or in routine surveillance of
hepatopathic patients. In oncologic patients, the liver is the most common target of metastatic disease and accurate
detection and characterisation of FLLs is prognostically fundamental during the initial staging as well as before and
after pre-operative chemotherapy, as it can help to identify patients who are most likely to benefit from liver surgery.
Moreover, early detection of primary or secondary liver malignancies increases the possibility of curative surgical
resection or successful percutaneous ablation. As many FLLs in these patients are benign, a precise and preferably
non-invasive method of differentiation from malignant metastatic nodules is needed. Moreover, the continuous follow-
up of cancer patients requires an easily available, reliable and cost-effective diagnostic tool for the detection and
characterization of FLLs.
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Focal liver lesions (FLLs) are frequently discovered
during ultrasound examinations either in healthy subjects
without a clinical history of cancer or during staging or
follow-up procedures in oncologic patients or in routine
surveillance of hepatopathic patients. In oncologic
patients, the liver is the most common target of meta-
static disease and accurate detection and characterisation
of FLLs is prognostically fundamental during the initial
staging as well as before and after pre-operative chemo-
therapy, as it can help to identify patients who are most
likely to benefit from liver surgery. Moreover, early
detection of primary or secondary liver malignancies
increases the possibility of curative surgical resection or
successful percutaneous ablation[1,2]. As many FLLs
in these patients are benign, a precise and preferably
non-invasive method of differentiation from malignant
metastatic nodules is needed. Moreover, the continuous
follow-up of cancer patients requires an easily available,
reliable and cost-effective diagnostic tool for the detec-
tion and characterisation of FLLs.
Ultrasound is a widely used method for the detection
of FLLs; however there are limitations to conventional
grey scale B mode ultrasound, especially when the
lesions are small (52 cm), when cirrhosis is present or
in patients undergoing chemotherapy. Colour and power
Doppler have increased sensitivity for detection of FLLs
compared to conventional B mode, but sensitivity is still
inferior to contrast-enhanced computed tomography
(CT) and magnetic resonance imaging (MRI)[1,3!5]. To
improve the detection of FLLs, sonography must also
provide information on vascularity, exploiting differences
in blood supply between normal and pathologic tissue.
The introduction of microbubble contrast agents and
the development of contrast-specific techniques have
opened new perspectives in liver ultrasound (US).
Contrast-enhanced ultrasound (CEUS) represents a sig-
nificant breakthrough in sonography. Its unique
feature of non-invasive assessment in real-time of liver
perfusion throughout the different vascular phases has
led to a dramatic improvement in diagnostic accuracy
of US in the detection and characterisation of FLLs,
as well as in the guidance and evaluation of response
to therapeutic procedures. The technique is based on a
new class of intravascular microbubble agent, consisting
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of perfluoro-gases combined with multipulse scanning
modes sensitive to non-linear (harmonic) responses of
the microbubbles and enabling tissue signal
suppression[6,7].
With harmonic ultrasound imaging, thanks to blood-
pool contrast agents, it is possible to have real-time obser-
vation of the contrast-enhancement in the different
phases with high spatial and contrast resolution, thus
allowing precise evaluation of tumoral vascularisation,
outlining both macro- and micro-circulation.
Unlike contrast agents used for CT and MR, second
generation contrast media may truly distribute intravas-
cularly without any interstitial phase. In the delayed
phase of CEUS, microbubbles are entrapped in the
sinusoids, giving the so called "sinusoidal phase#, which
is the ideal phase for hepatic staging by CEUS, as it
allows the evaluation of the entire liver parenchyma.
Distribution and retention of the contrast microbub-
bles in the sinusoidal network without passage into the
interstitial space make the CEUS sinusoidal phase
fundamental in distinguishing between benign and malig-
nant lesions. During this phase, lesions with liver-like
(focal nodular hyperplasia (FNH), adenoma) or angio-
matous (cavernous and capillary hemangiomas) vascular
structures appear isoechoic or hyperechoic due to the
retention of microbubbles similar or superior to that in
the adjacent liver parenchyma. Conversely, in lesions
with neoangiogenic vascular structures (hepatocellular
carcinoma (HCC), cholangiocarcinoma, metastases), a
similar degree of retention of the microbubbles compared
to the liver parenchyma cannot be present. In particular,
metastases are easily differentiated from benign lesions
by their hypoechoic appearance in the late sinusoidal
phase compared to the liver parenchyma, which is
homogenously enhanced during the sinusoidal CEUS
phase, even though metastatic lesions may show various
contrast enhancement patterns in the arterial phase
(absent, rim-like, dotter or diffuse), similar to that of
the benign lesions[8!10]. The identification of a hypo-
echoic defect during the sinusoidal CEUS phase allows
the correct characterisation of the majority of malignant
focal liver lesions[9,11]. However, a clear hypoechoic
defect in the sinusoidal CEUS phase is expected to be
imaged even within fibrotic or necrotic areas of liver
lesions, due to the absence of delayed fibro-interstitial
enhancement, based on the absence of the pooling of
microbubble contrast agent. For this reason a sclerosed
hemangioma and a necrotic intrahepatic area, appearing
as a clear hypoechoic defect in the sinusoidal CEUS
phase, can be wrongly diagnosed as malignant lesions.
Several studies have shown an improved diagnostic
performance and confidence of CEUS in diagnosing
liver metastases when compared with baseline US.
With up-to-date technologies CEUS sensitivity, specificity
and accuracy in the detection of liver metastases is
comparable or superior to that obtained with contrast-
enhanced CT, with similar results to state of the art
liver MRI. CEUS has been shown to be particularly
useful to improve the conspicuity and detection rate of
metastases smaller than 1 cm or those lesions which are
isoechoic to the adjacent liver parenchyma and thus
barely visible at B mode ultrasound[7,12!14]. Real-time
observation gives to the CEUS technique high sensitivity
in discovering hypervascular lesions (such as small
metastasis due to hyper-vascularised tumours or small
HCC). Other techniques such as CT and MRI can
often fail in this purpose due to wrong arterial contrast
timing[9]. Moreover, microbubble-based contrast agents
allow diagnostic problems to be solved directly in the
US unit, without employing other imaging techniques,
with a consequent reduction in the waiting and hospital
time for the patient.
However, there are some intrinsic limitations in CEUS,
similar to those of B mode sonography: e.g. obese
patients with abundant meteorism, or deep lesions.
Furthermore, it is an operator dependent procedure
and a less reproducible and a less panoramic tool than
CT or MRI, especially when routine follow-up examina-
tion is needed. For these reasons CEUS is less widely
used than should be for detection and is often confined
to its better encoded role in characterising an equivocal
lesion discovered during the B mode exam or as a
"second-look# tool for atypical lesions studied with CT
and/or MRI, due to the intravascular and non-interstitial
distribution of the microbubbles[3,10,15,16].
CT is an easy access technique, due to wide availability
and patient-friendly protocols allowing even a
chest!abdomen!pelvis examination in less than 20 s
breath hold using multidetector CT technology. It has
high sensitivity and specificity for detecting hepatic
metastases and it is able to characterise the vast majority
of focal liver lesions, such as haemangiomas. However, it
often happens that a lesion is indeterminate on contrast-
enhanced CT. In this case, the principal technique for
additional liver evaluation after CEUS and contrast-
enhanced CT is MRI and it is rapidly emerging as the
imaging modality of choice for detection and character-
isation of focal liver lesions due to high sensitivity
and specificity, resulting from the optimal lesion-to-liver
contrast and no exposure to radiation. Improvement
in breath-hold T1 weighted fast spoiled gradient echo,
respiratory trigger applied to T2-weighted FSE sequences
and parallel imaging are crucial to obtain high quality
MRI liver images, reducing the most important artefacts
that derive from respiratory motion.
MRI gadolinium-chelate contrast agents provide
critical tumour characterisation, with high contrast and
spatial resolution information, and can be safely used in
patients allergic to iodine contrast agents. The advent
of liver-specific contrast agents, which are targeted to
enhance hepatocytes (hepato-specific contrast-agent
such as Gd-BOPTA, Gd-EOB-DTPA, Mn-DPDP) or
Kupffer cells (superparamagnetic iron oxide (SPIO)
and ultrasmall superparamagnetic iron oxide (USPIO),
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e.g. ferumoxide and ferucarbotran) has facilitated an
increase in accuracy of MRI in detection and character-
isation of FLLs[17!23].
Frequently the first step in MRI imaging is performing
a basal pre-contrast liver evaluation, followed by the
contrast dynamic imaging with an injection bolus
of liver-specific gadolinium-chelates like Gd-BOPTA or
Gd-EOB-DTPA, that have high T1 relaxivity properties,
allowing enhancement pattern analysis. Moreover, these
contrast agents are taken up by functioning hepatocytes;
thus after a variable amount of time after the injection
(20!120min, depending on the contrast agent),
the normal liver shows increased signal intensity on
T1 images, while a liver lesion becomes hyper-, iso- or
ipo-intense due to the presence or absence of normal
hepatocytes, often allowing the correct differentiation
between benign hepatocellular lesions and malignant
non-hepatocellular lesions.
Recently the rising importance of diffusion-weighted
imaging (DWI) in abdominal pathology has been
reported. Diffusion is a natural physical phenomenon,
due to brownian motion that is arbitrary and irregular,
caused by thermal movement. Despite the effect of
molecular diffusion, movement is weak, and it can
result in the MR signal missing convergence with the
degree of attenuation in the MR gradient intensity and
the amplitude of molecular movements. The diffusion
coefficient of the living body is affected by many factors
of macrocirculation such as cellular osmosis and temper-
ature, diffusion of capillaries, glutinous degree and pro-
portion of intra- and extracellular water and direction of
cellular transitions. It is also affected simultaneously by
macro factors and circadian rhythms, such as breath,
pulsation and peristalsis. The apparent diffusion coeffi-
cient (ADC) has been used to replace diffusion[24].
Recently DWI has been applied to regions of the body to
detect malignant lesions, due to high sensitivities of this
technique in the visualisation of lesions with higher cellu-
lar density[25]. For DWI breath-hold single-shot (SS)
spin-echo (SE) or echo-planar imaging (EPI) with fat sat-
uration is widely employed because of its speed and rela-
tively high signal-to-noise ratio. Parallel imaging is crucial
to reduce the acquisition time or increase the matrix,
improving spatial resolution, without altering the acquisi-
tion time and without significant loss of image quality[26].
In the post-processing phase, the DW images are used
to calculate the ADC maps on which the signal analysis
is performed by positioning a region of interest (ROI) on
the lesion being studied.
The choice of the degree of diffusion weighting
(b-value) is still an unresolved problem. In the literature
different b-values are used with different results[27].
Recently, different authors suggest acquiring three
sets of DW images with three different b-values[28!30].
To improve sensitivity in detection of small solid lesions
(51 cm) respiratory triggered SS-EPI-DWI is particularly
useful[30].
In liver imaging DWI is useful in the detection and
characterisation of focal lesions. It has recently been
shown that DWI is a very sensitive tool with higher
values compared to that of T2-weighted turbo spin echo
(TSE) or short tau inversion recovery (STIR) or half-
Fourier single-shot turbo spin echo (HASTE) images,
in the detection of solid focal liver lesions[30]. In charac-
terisation, the ADC values have a good accuracy
(83!88%) in discriminating between malignant and
benign lesions, due to the fact that ADCs of metastases
are significantly lower in most cases than those of benign
lesions like hemangiomas, FNHs and cysts, even if some
difficulties in differentiation are due to some overlap
of ADC values (i.e. high ADC values in metastatic
lesions with a high necrotic component or intermediate
ADC values in hepatic abscesses with dense viscous
content)[28,31,32].
Measurement of the ADCs of focal liver lesions may
constitute a useful supplementary method for lesion char-
acterisation both in healthy and oncologic patients,
improving the information from basal pre-contrast MR
sequences, contrast-dynamic imaging and delayed imag-
ing with hepato-specific contrast agents.
In conclusion, the first step in the follow-up of onco-
logic patients is still B mode ultrasound, followed by
CEUS when an incidental focal liver lesion is discovered.
Even if contrast-enhanced CT, due to its wide diffusion
and good sensitivity and specificity, is still the method of
choice for the evaluation of oncologic patients, MRI
should be considered the imaging modality of choice
when characterisation of a focal liver lesion is crucial
for therapeutic decisions, especially when a benign liver
lesion in suspected in a patient with cancer, due to its
high specificity derived from multimodality MR imaging
(dynamic contrast imaging, hepato-specific contrast
agents delayed imaging and diffusion-weighted imaging).
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